Multimodal Approaches to Improve Immunotherapy in Breast Cancer
- 1 February 2020
- journal article
- editorial
- Published by Taylor & Francis in Immunotherapy
- Vol. 12 (3) , 161-165
Abstract
No abstract availableKeywords
This publication has 41 references indexed in Scilit:
- SEMA4D compromises blood–brain barrier, activates microglia, and inhibits remyelination in neurodegenerative diseaseNeurobiology of Disease, 2015
- Bevacizumab: A Review of Its Use in Advanced CancerDrugs, 2014
- Expression of glutamine metabolism-related proteins according to molecular subtype of breast cancerEndocrine-Related Cancer, 2013
- Bystander killing of cancer requires the cooperation of CD4+ and CD8+ T cells during the effector phaseJournal of Experimental Medicine, 2010
- IDO: A double-edged sword for TH1/TH2 regulationImmunology Letters, 2008
- Tumor angiogenesis and progression are enhanced by Sema4D produced by tumor-associated macrophagesJournal of Experimental Medicine, 2008
- Inhibitory effect of tumor cell–derived lactic acid on human T cellsBlood, 2007
- Indoleamine 2, 3-dioxygenase (IDO) is essential for dendritic cell activation and chemotactic responsiveness to chemokinesCell Research, 2005
- Breast cancer classification and prognosis based on gene expression profiles from a population-based studyProceedings of the National Academy of Sciences, 2003
- T cell apoptosis by tryptophan catabolismCell Death & Differentiation, 2002